BiotechTube
Home/Pipeline/Utreloxastat (PTC857)

Utreloxastat (PTC857)

Amyotrophic Lateral Sclerosis (ALS)

Phase 2Clinical

Key Facts

Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Phase 2
Status
Clinical
Company
PTC Therapeutics

About PTC Therapeutics

PTC Therapeutics is a patient-centric, publicly traded biopharma leader dedicated to translating groundbreaking science into life-changing treatments for rare diseases. Its key achievements include commercializing a series of 'firsts' in rare disease treatment and building a diversified pipeline targeting neurological and metabolic disorders. The company's strategic direction is fueled by its deep expertise in two core scientific platforms—splicing modifiers and inflammation/ferroptosis inhibitors—and a robust global commercial infrastructure to support its mission of delivering transformative medicines worldwide.

View full company profile

Therapeutic Areas

Rare Neurological DiseasesMetabolic DisordersNeuromuscular Disorders

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

DrugCompanyPhase
SAR443820/DNL788Denali TherapeuticsPhase 2
PegcetacoplanApellis PharmaceuticalsPhase 2
RELYVRIO/ALBRIOZA (AMX0035)Amylyx PharmaceuticalsApproved/Commercial
AMX0035Amylyx PharmaceuticalsPhase 3
AMX0114Amylyx PharmaceuticalsPhase 1
Taldefgrobep alfaBiohavenPhase 2/3
AMT-162uniQurePreclinical
AAV-UPF1MeiraGTxPreclinical
TegoprubartEledon PharmaceuticalsPhase 2
Intranasal ForalumabTiziana Life SciencesPhase 2
TDP-43 ProgramKorro BioDiscovery
COYA 302Coya TherapeuticsPhase 2